Redeye updates its estimates following Surgical Science’s Q1 2023 report, which took our forecasts to the woodshed. Educational Products sales came in c35% above our estimate. The company posted strong EBITDA and EBIT margins; both c2%-points higher than we anticipated. We believe that growth will moderate in the future while margin expansion continues. We raise our estimates and valuation.